Limits added to Zelnorm in the U.S.

04/2/2008 | Reuters

The FDA and Novartis AG announced that Zelnorm, a treatment for irritable bowel syndrome, will be restricted to patients requiring hospitalization or with life-threatening conditions. The agency said the Swiss drugmaker voluntarily decided to further limit use of the drug, which has been available only through a special FDA-supervised program since last year after clinical-trial data linked it to heart risk.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA